Center for International Blood and Marrow Transplant Research (CIBMTR) Chronic Graft-Versus-Host-Disease (GVHD) Risk Score

Estimates prognostic risk in patients with chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation.

Recipient age at transplantation*

<29 years0

30–59 years+1

≥60 years+2

Prior acute GVHD*

Time from transplantation to chronic GVHD onset*

Serum bilirubin at chronic GVHD diagnosis*

≤2 mg/dL (≤34.2 μmol/L)0

>2 mg/dL (>34.2 μmol/L)+2

Karnofsky performance score*

≥80: normal activity or independent function0

<80: requires varying degrees of assistance+1

Platelet count at chronic GVHD diagnosis*

Donor type*

HLA-identical sibling, well-matched unrelated, or partially matched unrelated donor0

Other donor type+1

Disease status at transplantation*

Early disease0

Intermediate disease+1

Advanced disease+2

Donor-recipient sex mismatch*

Other combinations0

Female donor to male recipient+1

GVHD prophylaxis*

Cyclosporine plus methotrexate-based regimen0

Other prophylaxis regimen+1